Related Experiment Video
Updated: Apr 12, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP
1Department of Hematology, Qing-dao Central Hospital, Qing-dao, China. lyyycn@yeah.net.
Objective:
This work aims to observe the efficacy and safety of low-dose rituximab in combination with recombinant human thrombopoietin in treating immune thrombocytopenia (ITP).
Patients And Methods:
Fourteen ITP patients were treated four times with 100 mg qw of rituximab in combination with 300 µg/kg/d ih recombinant human thrombopoietin (rhTPO) for 14 d. Platelet count in peripheral blood, serum immunoglobulin, and lymphocyte subgroups by flow cytometry were detected regularly both pre- and post-treatment.
Results:
Among the 14 patients, seven complete responses, six responses, and one no response were obtained, with an overall response of 93%.
Conclusions:
Low-dose rituximab in combination with rhTPO is effective in treating ITP.
